News Concordia hiked drug price by 6,000%, says UK watchdog CMA provisionally finds Concordia overpriced thyroid drug.
News Concordia and Actavis face UK pricing probe Firms colluded to hike prices, says competition watchdog.
News MSD stops trials of BTK inhibitor for blood cancers MSD has stopped development of BTK inhibitor nemtabrutinib, acquired via its $2.7bn takeover of ArQule, after trial results pointed to a safety issue.
Sales & Marketing Sponsored Securing your ROI: Turning post-acquisition integration into... Join Forinnovia and Little Cube Consulting for a webinar on securing post-acquisition ROI.